Another highly specific, structurally distinct Menin–KMT2A interaction inhibitor, VTP50469, has also shown nanomolar‐range activity, effectively suppressing KMT2A‐target gene expression and cell proliferation in KMT2A‐rearranged leukemia models.98 This evidence concerns the gene MEN1 and leukemia.